GeneDx Projects $5M Adjusted Loss for Q2
Summary
GeneDx Holdings has provided guidance indicating an anticipated adjusted loss of $5 million for the second quarter. This forward-looking statement follows closely on the heels of the company's recent first-quarter earnings report, which included a significant miss on revenue and adjusted EPS, alongside a downward revision of its full-year 2026 revenue outlook. The projected Q2 loss suggests ongoing financial headwinds or a slower-than-expected path to profitability, reinforcing the negative sentiment established by the prior announcements. Traders will need to factor this specific guidance into their models, as it provides a clearer picture of near-term financial performance. Investors will be watching for further updates on the company's operational improvements and any changes to its financial trajectory.
At the time of this announcement, WGS was trading at $38.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $55.17 to $170.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.